A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | - | 0 |
| Net Income | -66M | -49M | -42M |
| EPS | $-0.45 | $-0.36 | $-0.31 |
| Free Cash Flow | -45M | -45M | -41M |
| ROIC | -24.4% | -39.4% | -28.6% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.12 | 0.06 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -71M | -57M | -50M |
| Operating Margin | 0.0% | - | - |
| ROE | -31.4% | -36.1% | -28.6% |
| Shares Outstanding | 178M | 138M | 138M |
| Metric | |||
|---|---|---|---|
| Income Statement | |||
| Revenue | 0 | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -50M | -57M | -71M |
| Op. Margin | N/A | N/A | 0.0% |
| Net Income | -42M | -49M | -66M |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -28.6% | -39.4% | -24.4% |
| ROE | -28.6% | -36.1% | -31.4% |
| ROA | -27.1% | -33.2% | -28.5% |
| Cash Flow | |||
| Op. Cash Flow | -41M | -45M | -45M |
| Free Cash Flow | -41M | -45M | -45M |
| Owner Earnings | -47M | -54M | -54M |
| CapEx | 30K | 44K | 0 |
| Maint. CapEx | 699K | 589K | 589K |
| Growth CapEx | 0 | 0 | 0 |
| D&A | 699K | 589K | 589K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 6.1M | 8.6M | 8.6M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | -220M |
| Cash & Equiv. | N/A | N/A | 220M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | 0.06 | 0.12 | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | 149M | 125M | 210M |
| Total Assets | 157M | 140M | 231M |
| Total Liabilities | 8.3M | 15M | 22M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -315M | -365M | -365M |
| Working Capital | 146M | 124M | 124M |
| Current Assets | 154M | 133M | 133M |
| Current Liabilities | 7.8M | 8.9M | 8.9M |
| Per Share Data | |||
| EPS | -0.31 | -0.36 | -0.45 |
| Owner EPS | -0.34 | -0.39 | -0.30 |
| Book Value | 1.07 | 0.91 | 1.18 |
| Cash Flow/Share | -0.29 | -0.32 | -0.37 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 138.3M | 138.3M | 177.9M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -12.0 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | 1.4 | 1.6 | 4.6 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | -19.7% | -22.2% | -4.7% |
| Market Cap | 206M | 202M | 968M |
| Avg. Price | 2.84 | 1.52 | 5.44 |
| Year-End Price | 1.49 | 1.46 | 5.44 |
Compass Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Compass Therapeutics, Inc. (CMPX) has a 5-year average return on invested capital (ROIC) of -34.0%. This is below average and may indicate limited pricing power.
Compass Therapeutics, Inc. (CMPX) has a market capitalization of $968M. It is classified as a small-cap stock.
Compass Therapeutics, Inc. (CMPX) does not currently pay a regular dividend.
Compass Therapeutics, Inc. (CMPX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Compass Therapeutics, Inc. (CMPX) generated $-45 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Compass Therapeutics, Inc. (CMPX) has a debt-to-equity ratio of 0.12. This indicates a conservatively financed balance sheet.
Compass Therapeutics, Inc. (CMPX) reported earnings per share (EPS) of $-0.36 in its most recent fiscal year.
Compass Therapeutics, Inc. (CMPX) has a return on equity (ROE) of -36.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Compass Therapeutics, Inc. (CMPX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Compass Therapeutics, Inc. (CMPX) has a book value per share of $0.91, based on its most recent annual SEC filing.